Barrier Capacity of Human Placenta for Nanosized Materials by Wick, Peter et al.
432  v o l u m e  118 | n u m b e r 3 | March 2010  •  Environmental Health Perspectives
Research
Humans have always been exposed to air-
borne particles through natural sources such 
as volcanoes, forest fires, or desert dust. After 
the Industrial Revolution in the 19th cen-
tury, emission of anthropogenic particles into 
the atmosphere significantly increased. This 
increased exposure to respirable fine particles 
(< 2.5 µm in diameter) and ultrafine particles 
(UFPs; < 0.1 µm in diameter). Epidemiologic 
and in vivo studies have shown potential toxic 
effects of fine particles and UFPs on human 
health (Kreyling et al. 2004; Oberdörster and 
Utell 2002). When inhaled, UFPs are depos-
ited in the respiratory tract and may provoke 
inflammation or granuloma formation in the 
lung and induce systemic effects such as pro-
thrombotic responses (Nemmar et al. 2008) 
or cardiovascular changes (Alfaro-Moreno et 
al. 2007; Kreyling et al. 2004; Nemmar et al. 
2007, 2008). Despite the presence of several 
highly efficient lung clearance mechanisms, 
different studies have shown that the transfer 
of nanoparticles from the lung to the blood 
is possible (Geiser et al. 2005; Nemmar et al. 
2005; Rothen-Rutishauser et al. 2006).
With the broad use of nanotechnology, 
intentional production of nanoobjects in the 
size range of 1–100 nm has further increased the 
number and variety of nanoparticles to which 
humans can be exposed. New applications of 
engineered nanoparticles in nanomedicine such 
as nanoparticulate contrast agents (Rudin and 
Weissleder 2003), cancer treatments (Thiesen 
and Jordan 2008), and vaccines (Reddy et al. 
2007) are in development that will be directly 
injected in the bloodstream of patients.
Most of the recent research dealing with 
potential health hazards of nanoparticles has 
focused on cells and tissues that are likely to 
come into immediate contact with airborne 
particles. There is a growing concern about 
the possible influence on health of the expo-
sure to nanoparticles during pregnancy or early 
childhood (Lacasana et al. 2005). A recently 
performed cohort study suggests that prena-
tal exposure to air pollution might be associ-
ated with higher respiratory need and airway 
inflammation in newborns (Latzin et al. 2008). 
However, it remains unclear whether these 
effects were caused by particles crossing the pla-
centa or by mediators induced in the maternal 
circulation such as proinflammatory factors.
First indications that nanosized materials 
may cross the placental tissue came from a 
recent study in rats, showing that nanosized 
gold was transferred to the embryos 24 hr after 
intravenous injection (Semmler-Behnke et al. 
2007). However, these data cannot be extrap-
olated to humans because the anatomy and 
physiology of the human placenta are unique. 
One main difference is that in humans the 
syncytiotrophoblasts arise from the fusion of 
cytotrophoblast cells and form a true syncy-
tium with no lateral cell membranes, whereas 
in rats or mice three trophoblast layers are pres-
ent between maternal blood and fetal blood 
capillaries (for comprehensive reviews, see 
Enders and Blankenship 1999; Takata et al. 
1997). Thus, the transport efficiency for xeno-
biotics or nanoparticles across the placenta has 
to be defined for humans explicitly.
In detail, the cellular barrier between the 
maternal and the fetal blood is formed by 
the syncytiotrophoblast layer, which faces the 
maternal environment, and the endothelial 
cell layer of the fetal microcapillaries. Between 
these two cell layers there are several stromal 
cells such as cytotrophoblasts, fibroblasts, and 
Hofbaur cells (placental macrophages). This 
layer is relatively thick in early pregnancy and 
becomes progressively thinner with gestational 
age. This reduction in thickness together with 
an increase in the number of fetal capillar-
ies enhances the efficiency of maternal–fetal 
exchange during the development of the fetus 
(Enders and Blankenship 1999). The transfer 
of substances and the amount that enters the 
fetal circulation are tightly controlled by at 
least four different mechanisms: simple dif-
fusion, active transport, biotransformation 
through metabolic enzymes, and phagocytosis 
or pinocytosis (Syme et al. 2004). The plasma 
membrane of the syncytiotrophoblast is polar-
ized, consisting of the brush border mem-
brane that is in direct contact with maternal 
blood and the basal membrane that faces the 
fetal circulation (Ganapathy et al. 2000). The 
two membranes are further distinguishable 
from each other by their protein, receptor, 
and transporter composition. The brush bor-
der membrane contains specific transporters, 
such as those for serotonin (SER transporter) 
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Ba c k g r o u n d: Humans have been exposed to fine and ultrafine particles throughout their history. 
Since the Industrial Revolution, sources, doses, and types of nanoparticles have changed dramati-
cally. In the last decade, the rapidly developing field of nanotechnology has led to an increase of 
engineered nanoparticles with novel physical and chemical properties. Regardless of whether this 
exposure is unintended or not, a careful assessment of possible adverse effects is needed. A large 
number of projects have been carried out to assess the consequences of combustion-derived or engi-
neered nanoparticle exposure on human health. In recent years there has been a growing concern 
about the possible health influence of exposure to air pollutants during pregnancy, hence an implicit 
concern about potential risk for nanoparticle exposure in utero. Previous work has not addressed the 
question of whether nanoparticles may cross the placenta.
oB j e c t i v e: In this study we investigated whether particles can cross the placental barrier and affect 
the fetus.
Me t h o d s : We used the ex vivo human placental perfusion model to investigate whether nanopar-
ticles can cross this barrier and whether this process is size dependent. Fluorescently labeled polysty-
rene beads with diameters of 50, 80, 240, and 500 nm were chosen as model particles.
re s u l t s: We showed that fluorescent polystyrene particles with diameter up to 240 nm were taken 
up by the placenta and were able to cross the placental barrier without affecting the viability of the 
placental explant.
co n c l u s i o n s: The findings suggest that nanomaterials have the potential for transplacental transfer 
and underscore the need for further nanotoxicologic studies on this important organ system.
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or carnitine (novel organic cation transporter 
OCTN2), or unspecific transporters such as 
P-glycoprotein, a member of the multidrug-
resistance gene family. The folate transporter 
FOLT1, together with the folate receptor 
of the brush boarder membrane, is typically 
expressed in basal membrane and mediates 
the transport of vitamins across the placenta 
(Ganapathy et al. 2000).
The dual recirculation human placental 
perfusion model (Panigel et al. 1967; Schneider 
et al. 1972) provides a controlled system for 
studying the transplacental transport of various 
substances and is commonly used for pharma-
cokinetic studies. In the present study we used 
this model to investigate whether nanoparticles 
can cross the placental barrier and whether 
this process is size dependent. We chose fluo-
rescently labeled polystyrene (PS) beads with 
diameters of 50, 80, 240, or 500 nm as model 
particles. In addition, we assessed the viability 
and functionality of the placenta after particle 
perfusion.
Materials and Methods
Polystyrene beads. Fluorescent PS particles 
of 50 and 240 nm were commercially avail-
able from Kisker (PFP-00552 and PFP-0252; 
G. Kisker GbR, Steinfurt, Germany), and 
80- and 500-nm beads were purchased from 
Polyscience (catalog nos. 17150 and 17152; 
Polyscience Europe GmbH, Eppelheim, 
Germany). The particle stock solution was 
vortexed 15 min before each perfusion assay.
Characterization of PS bead suspension. 
We used a scanning electron microscope 
(SEM; S-4800, Hitachi High-Technologies 
Europe GmbH, Krefeld, Germany) to ana-
lyze the visual appearance of the as-received 
PS beads. We measured the size distribution 
of the PS beads in perfusion medium with a 
NanoSight LM 20 System (NanoSight Ltd., 
Amesbury, Wiltshire, UK) at a particle con-
centration of about 106 to 109 particles/mL 
and are presented as size–density plots. The 
density plot of the perfusion medium without 
beads has been reduced by a factor of 5 com-
pared with particle measurement in relation to 
the number of counting events measured.
We tested the stability of the fluorescent 
PS beads in different solutions, including the 
perfusion medium. Briefly, the beads were 
diluted with phosphate-buffered saline (pH 
4), 1% sodium dodecyl sulfate, 100% etha-
nol, and perfusion medium to a concentra-
tion of 10 µg/mL and incubated for 24 hr 
at 37°C. The fluorescence of 100 µL suspen-
sion was measured before and after filtra-
tion with a 0.1-µm Pall Acrodisc hydrophilic 
polyethersulfone filter (Pall Corporation, Port 
Washington, NY, USA), using a microplate 
reader (BioTex FLx800; Witec AG, Littau 
LU, Switzerland) with excitation and emission 
wavelengths of 485 and 528 nm, respectively.
We determined the detection limit of PS 
beads for each type of particles separately by 
serial dilution in perfusion medium in the range 
of 0.02–10 µg/mL. The detection limit was 
defined as the lowest concentration that showed 
a significant increase in the fluorescent intensity 
compared with pure perfusion medium.
We measured zeta potentials of different 
PS bead suspensions using a Malvern zetame-
ter (Malvern Instruments Ltd, Malvern, 
Worcestershire, UK). First, PS beads were dis-
persed in water to a concentration of 1 mg/mL 
by vortexing for 10 min. A second suspension 
was obtained by vortexing the PS beads in per-
fusion medium for 10 min.
Ex vivo dual recirculating human pla-
cental perfusion model. The placental perfu-
sion technique was originally developed by 
Panigel et al. (1967) and was further improved 
by Schneider et al. (1972). The dual recir-
culating perfusion was performed according 
to Malek et al. (2009). Intact placentas were 
obtained from uncomplicated term pregnan-
cies either after vaginal or cesarean delivery at 
the Department of Obstetrics of the University 
Hospital Zurich. All mothers gave written 
informed consent for the use of the placen-
tas in this study. To minimize damage, the 
placentas were placed in 200 mL of a 0.9% 
sodium chloride solution preheated to 37°C, 
and then transported in a Styrofoam box to 
the research laboratory within 20 min of deliv-
ery. To perfuse the fetal side, the artery and 
vein of an intact cotyledon were cannulated. 
Subsequently, the placental tissue was fixed in 
a tissue holder and then placed into a perfusion 
chamber. The maternal side was perfused by 
introducing three blunt metal cannulas into the 
intervillous space by penetration of the decid-
ual plate. Furthermore, a venous drain, con-
nected with a peristaltic pump (Reglo Digital; 
Ismatec, Glattbrug, Switzerland) removed the 
perfusate from the chamber and returned it 
to the maternal reservoir. Fetal and maternal 
cannulas were connected to separate perfusion 
circuits. Peristaltic pumps held the fetal circuit 
flow at a rate of 6.0 mL/min and the maternal 
circuit at 12.0 mL/min.
The perfusion medium is composed of 
NCTC-135 tissue culture medium (ICN 
Biomedicals, Inc., Irvine, CA, USA) diluted 
with Earl’s buffer (1:1) supplemented with 
glucose (G 7528, 2 g/L; Sigma Switzerland, 
Buchs SG, Switzerland), dextran 40 (10 g/L; 
Sigma 31389), bovine serum albumin 
(8 g/L; Sigma), sodium heparin (2,500 IU/L; 
GlaxoSmithKline AG, Münchenbuchsee, 
Switzerland), and amoxicillin (Clamoxyl, 500 
mg/L; GlaxoSmithKline). Two oxygenators 
(LSI-OX, Living Systems Instrumentation Inc., 
Burlington, NH, USA) were used, one with 
95% N2 and 5% CO2 for the fetal circuit, and 
one with 95% air and 5% CO2 for the mater-
nal perfusate. Both perfusates were maintained 
at a temperature of 37°C by a water bath (Glas 
water bath; UNI-GLAS, Zürich, Switzerland). 
The experiments included a 20-min period of 
open perfusion of both compartments (pre-
phase) to flush the blood out of the intervillous 
space and the villous vascular compartment and 
to allow recovery of the placental tissue from 
the ischemic period after delivery. After the 
prephase, the maternal perfusate was exchanged 
with a perfusate containing PS beads of 50, 80, 
240, or 500 nm, respectively, at a final concen-
tration of 25 µg/mL and 14C-antipyrine (50 
nCi/mL; specific activity, 4.7 mCi/mmol). The 
experiment was continued in closed maternal 
and fetal circuits with equal starting volumes 
of 120 mL. After 180 min the same amount of 
beads was added to the maternal circuit. The 
integrity of the fetal circulation was monitored 
by assessing the leak in the fetal-to-maternal 
direction, including the measurement of the 
volume loss of the fetal perfusate.
The criteria for a successful perfusion were 
a) visual control: intact membranes, no lesion, 
no disruption of the placenta; b) leak from 
fetal to maternal side < 4 mL/min (Malek et 
al. 1994); c) 14C-antipyrine values: equilibrium 
between maternal and fetal circuit after 4–6 
hr (Challier 1985); d) fetal perfusion pressure 
< 70 mm Hg at all times; and e) fetal pH at 
physiologic range of 7.2–7.4. To determine 
the concentration of fluorescent PS particles 
in the maternal and fetal circuit, we removed 
100 µL perfusion medium from each circuit at 
the indicated time points. After centrifugation 
at 800 rpm to remove residual erythrocytes, 
fluorescence was read at 485-nm excitation 
and 528-nm emission in a microplate reader 
(BioTex FLx800, Witec AG).
Permeability and viability of the placen-
tal tissue. We evaluated the permeability of 
the placenta by monitoring the transplacen-
tal transfer of 14C-antipyrine as described pre-
viously (Challier 1985). Briefly, 50 nCi/mL 
14C-antipyrine were added to the maternal 
circuit, and 300 µL of the perfusion medium 
from each reservoir was transferred into sepa-
rate scintillation tubes and mixed with 3 mL 
scintillation cocktail (Irgasafe Plus Scintillation 
Cocktail, Zinsser Analytic, Frankfurt, 
Germany). 14C radioactivity was immediately 
measured for 5 min in a beta counter (Packard 
Tri-Carb 2200 liquid scintillation analyzer; 
GMI, Ramsey, MN, USA). Maintenance of 
placental function was assessed by measuring 
the production and accumulation of the two 
placental hormones leptin and human cho-
rionic gonadotropin using an enzyme-linked 
immunosorbent assay as described previously 
(Malek et al. 2000, 2001). Briefly, the net pro-
duction (NP) of human choriongonadotropin 
or leptin was estimated as NP = (end tissue 
content minus initial tissue content) plus accu-
mulation. To determine the metabolic activity 
of the placenta, we used the sum of changes Wick et al.
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in total (maternal and fetal) content over time 
divided by the perfused cotyledon weight to cal-
culate glucose consumption or lactate produc-
tion, which were measured with an automated 
blood gas system (ABL800 FLEX automated 
benchtop analyzer; Radiometer Medical ApS, 
Copenhagen, Denmark).
Detection of PS beads in the fetal cir-
cuit after perfusion. A 1.5-mL sample of the 
fetal perfusion medium was taken after 6 hr 
of perfusion and was centrifuged at 25,000 
relative centrifugal force for 30 min at 4°C. 
This allowed the concentration of PS beads 
> 50 nm in the pellet, because no fluores-
cent signals were detected in the supernatant 
after centrifugation. The pellet was washed 
Figure 1. SEM and size distribution of PS beads. (A–D) SEM micrographs depict the beads with diameters of 50 nm (A), 80 nm (B), 240 nm (C), and 500 nm (D). 
(E) The size distributions of all applied particles were measured in the perfusion medium, presented as a size–density plot.
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Figure 2. Perfusion profiles of PS beads and 14C-antipyrine. After the prephase, PS beads of different sizes were added to the maternal circuit to a final concen-
tration of 25 µg/mL and the amount of 14C-antipyrine and PS beads in both maternal circuits (M, solid symbols) and fetal circuits (F, open symbols) were measured 
after the indicated time points. (A) In the fetal circuit, significantly increased levels of 50-, 80-, and 240-nm PS beads were measured after only a few minutes 
of perfusion, whereas the 500-nm beads were retained in the placental tissue and maternal circuit. A second addition of particles after 180 min (arrow) did not 
further increase the amount of beads in the fetal circuit. (B) The perfusion profiles of 14C-antipyrine were not affected by the presence of beads and maintained 
equilibrium until the end of the perfusion assay. Data represent mean ± SE of at least four independent experiments.
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Table 1. Summary of PS bead characteristics.
PS beads
Characteristic 50 nm 80 nm 240 nm 500 nm
Diameter (nm)a 49 83 240 504
Diameter (nm)b 43 ± 35 81 ± 44 220 ± 60 370 ± 96
Surface area (nm2)c 1.88E+03 5.41E+03 4.52E+04 2.00E+05
Internal volume (nm3)c 6.16E+04 2.99E+05 7.24E+06 6.70E+07
Density of PS (mg/nm3)d 1.05E–18 1.05E–18 1.05E–18 1.05E–18
Mass of one PS particle (mg)c 6.47E–14 3.14E–13 7.60E–12 7.04E–11
Initial PS particles/mL PMc 3.87E+11 7.95E+10 3.29E+09 3.55E+08
PS particle surface/mL PM (nm2)c 7.28E+14 4.30E+14 1.49E+14 7.10E+13
Detection limit of PS (µg/mL)b < 1.25 < 1.64 < 0.63 < 0.21
Detection limit of PS (no./mL)c 1.94E+10 5.22E+09 8.22E+07 2.96E+06
Zeta potential in DD water (mV)b –58.7 ± 2.26 –56.4 ± 2.12 –32.7 ± 0.78 –42.3 ± 0.49
Zeta potential in PM (mV)b –6.23 ± 0.20 –7.40 ± 0.70 –8.91 ± 0.74 –12.8 ± 1.20
Abbreviations: DD, double distilled; PM, perfusion medium. 
aAccording to manufacturer’s information. bExperimentally determined (mean ± SE). cCalculated values. dFrom literature 
(Sharp and Beard 1950). Placental barrier capacity for nanoparticles
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once with Millipore water, applied onto a 
carbon-coated copper grid (400 mesh; Pelco, 
Redding, CA, USA) and processed for trans-
mission electron microscopy (TEM) analysis.
Statistical analysis. Data are shown as 
mean ± SE from at least four independent 
experiments. Statistical analysis was made 
with the Mann–Whitney two-sample test and 
the Wilcoxon test. A p-value < 0.05 was con-
sidered to be statistically relevant.
Results
PS particle characterization. Table 1 sum-
marizes details of particle characterization, 
such as particle size, surface area, and total 
surface charge in pure water and in perfusion 
medium. The zeta potential measurement of 
the PS beads in perfusion medium resulted in 
slightly negative values ranging from –12.8 ± 
1.20 to –6.23 ± 0.20 mV, indicating that the 
albumin stabilizes the spheres in the perfu-
sion medium. Size distribution analysis con-
firmed that suspensions of 50-nm, 80-nm, and 
240-nm beads were relatively monodisperse 
(Figure 1A–C, E). However, we observed par-
ticles of various sizes in SEM images as well as 
in size–density plots of 500-nm suspensions 
(Figure 1D, E).
The use of fluorescent nanoparticles, espe-
cially of PS beads, has been shown to cause 
experimental problems because of a possible 
transfer of the lipophilic dye to the surround-
ing tissue and/or cells (Kanno et al. 2007; 
Pietzonka et al. 2002). To exclude false-positive 
results, we measured the stability of the fluores-
cent dye in different solutions, including our 
perfusion medium. Except for pure ethanol, 
where we detected a release of 33.7 ± 0.74% of 
the fluorescent dye for 240-nm beads and 35.9 
± 10.2% for 500-nm beads, the fluorescence 
remained stable in all tested conditions, includ-
ing our perfusion medium (data not shown).
We experimentally determined the detec-
tion limit of the fluorescent PS particles in 
perfusion medium for each particle size. The 
minimum concentration of particles that still 
allowed the detection of a significant fluo-
rescent signal was 1.25 µg/mL for 50-nm, 
1.64 µg/mL for 80-nm, 0.63 µg/mL for 
240-nm, and 0.21 µg/mL for 500-nm beads 
(Table 1).
Perfusion profiles of PS beads of different 
sizes. Another important control was to assess 
the quality of the placental explant, which we 
achieved by monitoring the diffusion of 14C-
antipyrine, which is known to rapidly cross the 
placenta and reach equal concentration in the 
maternal and fetal circuit after 4–6 hr (Challier 
1985) (Figure 2B). If we started the perfusion 
with 25 µg/mL 50-nm PS beads in the mater-
nal circuit, the level of particles measured after 
180 min was 8.90 ± 1.80 µg/mL in the fetal 
perfusion medium and 18.1 ± 5.64 µg/mL in 
the maternal perfusion medium (Figure 2A). 
Because these concentrations remained stable 
thereafter, we performed a second adminis-
tration of the same amount of beads to test 
whether the number of beads in the fetal cir-
cuit could be further increased. Similar to 
the first injection of PS beads, we observed a 
gradual decrease of the particles in the mater-
nal perfusion medium but detected no sig-
nificant increase of beads in the fetal perfusion 
medium. Administration of 80-nm particles 
resulted in a perfusion profile similar to the 
one for 50-nm beads, and the concentration of 
80-nm particles measured in the fetal circula-
tion after 180 min was 7.47 ± 1.77 µg/mL. 
After perfusion with 240-nm PS particles for 
180 min, the bead concentration on the fetal 
side had dropped to 2.03 ± 0.29 µg/mL. Using 
500-nm PS beads, nearly all particles were 
retained in the maternal circulation or placental 
tissue, and the concentration of beads detected 
in the fetal circulation was 0.31 ± 0.21 µg/mL 
(Figure 2A). The level of particles was low most 
likely because the 500-nm bead suspension was 
not monodisperse but rather contained par-
ticles < 500 nm in diameter (Figure 1D). We 
used the ratio of fetal-to-maternal concentra-
tion of PS beads detected after 180 min to esti-
mate the amount of PS particles that crossed 
the placenta (Figure 3). These measurements 
showed that the translocation of PS beads 
across the placenta is clearly size dependent, 
and particles larger than 240 nm hardly pass 
this tissue barrier. The presence of PS beads 
did not affect the diffusion kinetic of 14C-anti-
pyrine (Figures 2B, and 3), indicating that PS 
particles did not alter the transfer properties of 
the placental tissue.
At the end of each perfusion experiment, 
we took samples from the fetal circuit to check 
for the presence of beads. TEM micrographs 
indeed showed beads with diameters of up to 
240 nm in the fetal perfusion medium (data 
not shown). This confirms the results of the flu-
orescence measurements that beads of around 
240 nm were able to cross the human placenta.
Viability of placental tissue after perfusion. 
The presence of PS beads in the placental tis-
sue did not affect the viability of the placental 
explant, because the consumption of glucose 
and the production of lactate, human chori-
onic gonadotropin, and leptin were not altered 
(Figure 4). In addition, structural analysis of 
the explant after perfusion showed no altera-
tions of the tissue, cells, or subcellular struc-
tures (data not shown).
Discussion
The main findings of this study are that PS 
beads up to a diameter of 240 nm were taken 
up by the placenta and, further, were able to 
cross the placental barrier without affecting 
the viability of the explant. We used fluores-
cently labeled negatively charged PS beads of 
50, 80, 240, and 500 nm as model particles 
because of their known biocompatibility and 
easy detection. This study provides evidence 
that the translocation of these beads across the 
placenta is size dependent.
We applied the particles at a single dose and 
at a high concentration, which can be assumed 
to be more representative of an intravenous 
injection, as reported for glioblastoma treat-
ment with magnetic nanoparticles (Thiesen and 
Jordan 2008), than an environmental exposure 
scenario. With the ex vivo perfusion model, the 
mechanism of nanoparticle transport through 
the placenta very close to the in vivo situation 
can be studied, but it is limited to a perfusion 
period of a few hours: Chronic treatments with 
low doses over a long period are not possible 
Figure 3. Size-dependent barrier capacity of the 
placental tissue. The ratios between fetal (F) and 
maternal (M) concentrations of 14C-antipyrine (open 
bars) and PS beads (blue bars) were calculated 
after 180 min of perfusion. The 14C-antipyrine values 
remain unchanged, whereas the perfusion rate of 
the beads showed size dependence. Data represent 
mean ± SE of at least four independent experiments. 
*p < 0.05 compared with 240-nm ratio value; **p < 0.05 
compared with 80-nm ratio value; #p < 0.05 compared with 
50-nm ratio value.
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because of tissue degradation (Panigel et al. 
1967; Schneider et al. 1972). A further limi-
tation of the model is that the perfusion rate 
measured in the explant represents only the late 
phase of pregnancy, for which the thickness of 
the barrier layer between the maternal and the 
fetal circuit is reduced and the number of fetal 
capillaries is increased (Enders and Blankenship 
1999). Thus, the perfusion rates obtained with 
the ex vivo perfusion model may be higher than 
during the greater part of pregnancy in vivo.
The consideration of the mass concentra-
tion of nanoparticles is often criticized, and 
instead surface concentration or particle num-
ber concentration are suggested as a model 
(Stoeger et al. 2006). In the present study we 
intentionally selected a highly biocompatible 
nanomaterial to specifically examine the barrier 
capacity of the placenta without inducing toxic 
side effects. Thus, in this particular case, particle 
surface–dependent or mass-dependent toxicities 
play minor roles. Nevertheless, all relevant par-
ticle characteristics are summarized in Table 1 
for later comparison and interpretation.
Possible transport routes for nanoparticles 
across the placenta are diffusion, vesicular trans-
port, transmembranal transporter proteins, and 
the transtrophoblastic channel system. The per-
fusion profiles obtained for the 50- and 80-nm 
beads could be interpreted to suggest that these 
particles cross the placenta very quickly by sim-
ple diffusion. If so, the second application of 
PS beads should lead to a continuous translo-
cation of the beads, which is not the case. The 
high doses applied could have induced dra-
matic clogging of the intervillous space on the 
maternal side, such that transfer routes were 
nearly blocked. Vesicle transport such as clath-
rin- or caveolin-mediated uptake is likely for the 
smaller PS particles because of their restricted 
size of 60 nm for clathrin-coated vesicles and 
120 nm for caveolin-coated vesicles but rather 
questionable for bigger spheres of 240 nm 
(for comprehensive reviews, see Conner and 
Schmid 2003; Hillaireau and Couvreur 2009). 
The extent to which placenta transporter pro-
teins in the basal- or brush-border membrane 
(e.g., of the syncytiotrophoblast) are involved in 
the nanoparticle transport remains unclear. The 
transtrophoblastic channel system represents a 
continuous membrane-lined tubular structure 
of about 20 nm in diameter that connects the 
intervillous space with the stroma and may act 
as a pressure-dependent valve regulating fetal 
water balance (Kertschanska et al. 1997). If 
the arterial pressure exceeds 80 cm H2O (cor-
responding to around 60 mmHg), this chan-
nel system is dilated, allowing the transport of 
liquid and small molecules. Whether this is true 
for the PS beads in our perfusion experiments 
requires further detailed investigations.
The critical size for PS nanoparticles to 
cross a placental barrier seems to be consis-
tent with observations made at the air–blood 
barrier, where fluorescent PS beads of around 
200 nm diameter penetrated cells in an energy-
independent way (Geiser et al. 2005). But the 
capability of nanomaterials to cross the placenta 
appears to depend not only on particle size but 
also on the material composition or surface 
coating. It has been shown that polyethylene 
glycol–coated gold particles up to 30 nm in 
diameter were not able to cross the placenta 
with the same experimental setup as used in the 
present study (Myllynen et al. 2008). The fact 
that PS beads and gold nanoparticles interact 
differently with biological compounds suggests 
that, in general, the capability for transplacen-
tal transfer mechanism(s) has to be assessed 
separately for each type of nanoparticle.
Conclusion
Our study showed a clear size-dependent bar-
rier capacity of a healthy human placenta for 
PS nanoparticles, including an analysis of the 
viability and functionality of the tissue after 
the perfusion. We suggest that nanoparticles, 
in general, therefore have the potential for 
transplacental transfer. This potential under-
scores the need for further nanotoxicologic 
studies on this important organ system.
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